Business Wire

Democratising access to quantum computing: IQM Quantum Computers launches “IQM Spark” for universities and labs

30.8.2023 11:55:00 EEST | Business Wire | Press release

Share

IQM Quantum Computers (IQM), the European leader in building quantum computers, today launched “IQM Spark,” comprising a superconducting quantum computer and tailored learning experiences for universities and research labs worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830120669/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IQM Spark quantum computer (Photo: Business Wire)

IQM Spark comes pre-installed with a 5-qubit quantum processing unit, with more options available allowing for a wide variety of research experiments.

To help universities kick-start their quantum program, in addition, universities will have free maintenance for one year, and IQM will also provide training for running the system and learning materials accessible through IQM Academy, a user-friendly online platform. With IQM Spark, students of all levels (bachelor, master, and PhD) will have the opportunity to learn hands-on about quantum computing.

Additionally, universities can also provide their students with the skillset needed for a quantum-enabled future by leveraging both hardware and software within the learning materials. With its technical track record and world-class expertise, IQM is also committed to collaborating with universities to drive advancements in quantum science.

Dr. Kuan Yen Tan, Chief Technology Officer and Co-founder of IQM Quantum Computers, said: “Since our inception, we’ve invested in and promoted quantum education and the advancement of research, and it’s apparent that universities around the globe need critical tools like IQM Spark to train the workforce needed for the next generation. Given the potential of quantum computing, the ecosystem will require a wide range of talent across electronics, chip fabrication, hardware design, and software engineering. We are confident that our system will facilitate the learning experience and engage students with the physical system.”

“We’ve designed this offering for universities and research labs to build up their quantum expertise and we believe that our system will not only perform fundamental quantum experiments and raise interest in Science, Technology, Engineering, and Mathematics (STEM) but we will also advance university science around quantum computing in general, while addressing the shortage of talent and providing value for the job market,” Dr. Björn Pötter, Head of Product at IQM Quantum Computers, points out.

IQM has already delivered 5-qubit quantum computers to some universities and research institutions, including the VTT Technical Research Centre of Finland and the Leibniz Supercomputing Centre in Germany. The quantum computer at VTT has been connected to LUMI, Europe’s most powerful supercomputer, hosted by the CSC - IT Center for Science.

“VTT and IQM successfully collaborated in delivering Finland’s first quantum computer in 2021. The 5-qubit quantum computer enables users to take the first steps in developing quantum algorithms and learn how to utilise the new technology in practice”, said Pekka Pursula, Research Manager in Quantum Technologies at VTT.

“On-premises quantum hardware is only available from a very limited number of vendors. This fact alone makes it hard for us to provide this leading-edge hardware to our scientists. Pricing and missing learning resources make it even harder to make this leading-edge technology available for educational purposes for our students,” said Prof. Dr. Dieter Kranzlmüller, Chairman of the Board of Directors of the Leibniz Supercomputing Centre, which caters to all universities of Bavaria in Germany.

“IQM Spark will address three major challenges: availability, learning resources, and affordability. In that way, universities can give practical experience to the next generation of quantum computing experts,” he added.

“Making on-premises quantum computer hardware available to our scientists and students as a low-barrier resource will give a boost to scientific progress and educate the next generation of quantum experts. This paves the way for students in Bavarian universities, such as Ludwig Maximilian University of Munich (LMU) and Technical University of Munich (TUM) students, to become entrepreneurs in the field of quantum technologies and live up to the excellence claim of the Munich universities,” he concluded.

About IQM Quantum Computers:

IQM is the European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific, co-design approach. IQM’s commercial quantum computers include Finland’s first commercial 54-qubit quantum computer with VTT, IQM-led consortium’s (Q-Exa) HPC quantum accelerator in Germany, and IQM processors will also be used in the first quantum accelerator in Spain. IQM has over 280 employees with offices in Paris, Madrid, Munich, Singapore, and Espoo.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sylwia Barthel de Weydenthal, Head of Marketing and Communications
Email: press@meetiqm.com
Mobile: +358505966629
www.meetiqm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye